These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 3259620

  • 21. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE, Lipford EH, Mulé JJ, Rosenberg SA.
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Nov; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

  • 24. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA.
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [Abstract] [Full Text] [Related]

  • 25. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB.
    Cancer Res; 1988 Jun 15; 48(12):3461-9. PubMed ID: 3259468
    [Abstract] [Full Text] [Related]

  • 26. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.
    Sugarbaker PH, Matthews W, Steller EP, Eggermont AM.
    J Biol Response Mod; 1987 Aug 15; 6(4):430-45. PubMed ID: 3498012
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M, Snyderman CH, Heo DS, Johnson JT, d'Amico F, Herberman RB, Whiteside TL.
    Cancer Res; 1990 May 15; 50(10):3113-8. PubMed ID: 2334906
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun 15; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 31. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ, Barth RF, Clendenon NR, Gordon WA.
    Cancer Res; 1990 Jul 15; 50(14):4338-43. PubMed ID: 2364388
    [Abstract] [Full Text] [Related]

  • 32. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R.
    J Immunol; 1998 Dec 15; 161(12):6977-84. PubMed ID: 9862733
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice.
    Gallinger S, Hoskin DW, Mullen JB, Wong AH, Roder JC.
    Cancer Res; 1990 Apr 15; 50(8):2476-80. PubMed ID: 2138507
    [Abstract] [Full Text] [Related]

  • 36. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ, Yang JC, Afreniere RL, Shu SY, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):285-94. PubMed ID: 3108401
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ.
    Cancer Res; 1988 Sep 01; 48(17):5007-10. PubMed ID: 3261630
    [Abstract] [Full Text] [Related]

  • 39. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T, Kuroki M, Arakawa F, Yamamoto T, Kuwahara M, Haruno M, Ikeda S, Matsuoka Y.
    Anticancer Res; 1998 Sep 01; 18(1A):17-24. PubMed ID: 9568050
    [Abstract] [Full Text] [Related]

  • 40. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA.
    Cancer Res; 1988 Aug 01; 48(15):4409-16. PubMed ID: 3260537
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.